Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 4 |
Descriptor
| Social Behavior | 5 |
| Autism | 4 |
| Pervasive Developmental… | 4 |
| Check Lists | 3 |
| Outcomes of Treatment | 3 |
| Behavior Problems | 2 |
| Pharmacology | 2 |
| Symptoms (Individual… | 2 |
| Withdrawal (Psychology) | 2 |
| Adolescents | 1 |
| Adult Programs | 1 |
| More ▼ | |
Source
| Journal of Autism and… | 2 |
| Autism: The International… | 1 |
| Journal of the American… | 1 |
| Research in Autism Spectrum… | 1 |
Author
Publication Type
| Journal Articles | 5 |
| Reports - Research | 4 |
| Reports - Evaluative | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Direct linkAnagnostou, Evdokia; Jones, Nancy; Huerta, Marisela; Halladay, Alycia K.; Wang, Paul; Scahill, Lawrence; Horrigan, Joseph P.; Kasari, Connie; Lord, Cathy; Choi, Dennis; Sullivan, Katherine; Dawson, Geraldine – Autism: The International Journal of Research and Practice, 2015
Social communication impairments are a core deficit in autism spectrum disorder. Social communication deficit is also an early indicator of autism spectrum disorder and a factor in long-term outcomes. Thus, this symptom domain represents a critical treatment target. Identifying reliable and valid outcome measures for social communication across a…
Descriptors: Autism, Pervasive Developmental Disorders, Interpersonal Communication, Interpersonal Competence
Erickson, Craig A.; Wink, Logan K.; Early, Maureen C.; Stiegelmeyer, Elizabeth; Mathieu-Frasier, Lauren; Patrick, Vanessa; McDougle, Christopher J. – Journal of Autism and Developmental Disorders, 2014
Rationale: An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). Objectives: We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I…
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Metabolism
Scahill, Lawrence; Hallett, Victoria; Aman, Michael G.; McDougle, Christopher J.; Arnold, L. Eugene; McCracken, James T.; Tierney, Elaine; Deng, Yanhong; Dziura, James; Vitiello, Benedetto – Journal of Autism and Developmental Disorders, 2013
There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to…
Descriptors: Autism, Pharmacology, Effect Size, Pervasive Developmental Disorders
Carminati, Giuliana Galli; Gerber, Fabienne; Baud, Marc Andre; Baud, Olivier – Research in Autism Spectrum Disorders, 2007
This study observes the evolution of persons with pervasive developmental disorders (PDD) and profound intellectual disabilities living in residences with a Program for Residents with Autism Spectrum Disorders (ASD) characterised by a different educator's presence ratio and different logistic accommodations. This population is characterised by the…
Descriptors: Autism, Program Effectiveness, Adults, Pervasive Developmental Disorders
Peer reviewedCroonenberghs, Jan; Fegert, Joerg M.; Findling, Robert L.; de Smedt, Goedele; van Dongen, Stefan – Journal of the American Academy of Child and Adolescent Psychiatry, 2005
Objective: To determine the long-term safety and effectiveness of risperidone for severe disruptive behaviors in children. Method: A multisite, 1-year, open-label study of patients aged 5 to 14 years with disruptive behaviors and subaverage intelligence was conducted. Results: Seventy-three percent of the 504 patients enrolled completed the study.…
Descriptors: Social Behavior, Psychiatry, Pharmacology, Child Behavior
